National Institute of Infectious Diseases: Baricitinib Plus Remdesivir Shows Promise for Treating COVID-19
December 12, 2020
December 12, 2020
WASHINGTON, Dec. 12 (TNSJou) -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infecti . . .
The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infecti . . .